


(OTCBB: CEMI)

INVESTOR PRESENTATION

January 2005





FORWARD-LOOKING STATEMENTS

Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC").

CHEMBIO AT A GLANCE



B U S I N E S S **P L A N**

- **Developer & Manufacturer of Rapid Diagnostic Tests – 55 Employed**
- **Focused on HIV, TB & Contract Development/Manufacturing**
 - Expand International Distribution of HIV Tests through Brazil Tech. Transfer Contract, PEPFAR, Global Fund, Distributors**
 - Obtain FDA Approval (PMA)**
 - Develop New HIV and TB Tests Using New Rapid Test Platforms**
 - Obtain USDA Registration/Approval for BSE (Mad Cow) and NHP TB Tests**
 - Obtain FDA 510(k) Clearance for Dental Bacteria Test**
 - Continue to Develop Complementary Strategic Alliances with Market & Technology Leaders**

Organization & Management Team

Total Employment- 55

Lawrence Siebert, President
Richard Larkin, CFO
Avi Pelossof, Sales & Marketing & Bus. Dev.
Javan Esfandiari, R&D
Rick Bruce, Operations
David Gates, Regulatory






Market for Rapid HIV and TB Testing

- Individuals tested in public health settings do not return or call back for test results from laboratory tests as they can take at least several days to process
- In order to achieve the WHO Goal of having 3 million people on treatment by 2005, each day 5,000 people need to be brought onto treatment and kept on it. In order to achieve this, about 500,000 people will need to be tested each day (Source: Global Business Coalition on HIV/AIDS).
- Rapid Tests Have Been Embraced by Public Health as the Solution
- Markets will also develop in the US, Europe and eventually even an OTC market may develop if there is a paradigm change in the treatment outcomes and disease stigma
- Rapid Tests for active pulmonary tuberculosis are crucial to controlling TB and TB/HIV co-infection. Our efforts are focused on establishing clinical data that show that our test can detect a statistically meaningful number of patients that are not detected from the standard sputum smear method.

FORMAT FLEXIBILITY: Barrel Format – Sure Check HIV

Sure Check™ HIV




Collect • Process • Analyze
3 in 1

- Sample collection, processing and analysis in one device
- Individually packaged for use as needed
- Fingerstick sample
- Uses only 3µl of whole blood
- On-site results in minutes
- Room temperature storage

For export use only. • This product not cleared for use in the U.S.

Sure Check™ HIV

A single-use, self-contained, closed system for the collection, processing and analysis of a whole blood, serum or plasma sample for the detection of antibodies to HIV 1 and 2.




Sure Check™ HIV is ideally suited for field or point-of-care testing.

- No additional equipment or supplies needed.
- Valid test performance is indicated by a pink/purple control line.
- Presence of antibodies against HIV 1 or 2 is indicated by a second pink/purple line.

- Components Include:**
- 1 Sampler with test strip
 - 1 Buffer vial
 - 1 Safety lancet
 - 1 Bandage
 - 1 Desiccant
 - 1 Disposable rack per kit

Clinical study performance data available upon request

*SIMPLE FINGERSTICK WHOLE BLOOD OPERATING PROCEDURE:



For product and distributor information, contact:

Chambio Diagnostic Systems, Inc.

Chambio Diagnostic Systems, Inc.
3661 Horseblock Road, Medford, New York 11763
Tel: (631) 924-1135 Fax: (631) 924-6033
E-mail: info@chambio.com, Website: www.chambio.com

*Please refer to the product insert for complete usage instructions
Catalog # HIV201: 25 test kit; HIV233: bulk tests.

For export use only - This product not cleared for use in the U.S.

Rev 1.0, 1103

